See more : Rome Resources Plc (RMR.L) Income Statement Analysis – Financial Results
Complete financial analysis of BriaCell Therapeutics Corp. (BCTX) income statement, including revenue, profit margins, EPS and key performance metrics. Get detailed insights into the financial performance of BriaCell Therapeutics Corp., a leading company in the Biotechnology industry within the Healthcare sector.
You may be interested
- Jain Marmo Industries Ltd. (JAINMARMO.BO) Income Statement Analysis – Financial Results
- Sun Pharmaceutical Industries Limited (SUNPHARMA.BO) Income Statement Analysis – Financial Results
- New Era Electronics Co., Ltd (4909.TWO) Income Statement Analysis – Financial Results
- Arctic Fish Holding AS (AFISH.OL) Income Statement Analysis – Financial Results
- Strategic Minerals Europe Corp. (SNTAF) Income Statement Analysis – Financial Results
BriaCell Therapeutics Corp. (BCTX)
About BriaCell Therapeutics Corp.
BriaCell Therapeutics Corp., an immuno-oncology biotechnology company, engages in developing immunotherapies for the treatment of cancer. Its lead candidate is Bria-IMT that is in Phase I/IIa clinical trial in a combination study with immune checkpoint inhibitors for the treatment of breast cancer. The company also has a cooperative research and development agreement with the National Cancer Institute for developing Bria-OTS, a personalized immunotherapy for advanced breast cancer; and BriaDx, a diagnostic test. BriaCell Therapeutics Corp. is headquartered in West Vancouver, Canada.
| Metric | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 | 2010 | 2009 | 2008 | 2007 | 2006 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Cost of Revenue | 82.58K | 15.53K | 15.14K | 15.57K | 13.99K | 14.27K | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Gross Profit | -82.58K | -15.53K | -15.14K | -15.57K | -13.99K | -14.27K | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Gross Profit Ratio | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
| Research & Development | 26.75M | 15.34M | 8.02M | 1.32M | 2.22M | 3.74M | 2.39M | 1.71M | 723.43K | 105.82K | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| General & Administrative | 6.15M | 7.94M | 7.27M | -3.67M | -1.37M | -932.17K | -1.05M | 876.16K | 942.02K | 1.33M | 436.17K | 423.86K | 556.06K | 1.05M | 323.27K | 203.86K | 0.00 | 0.00 | 0.00 |
| Selling & Marketing | -178.93K | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| SG&A | 5.97M | 7.94M | 7.27M | -3.67M | -1.37M | -932.17K | -1.05M | 876.16K | 942.02K | 1.33M | 436.17K | 423.86K | 556.06K | 1.05M | 323.27K | 203.86K | 114.12K | 129.06K | 8.58K |
| Other Expenses | 0.00 | 0.00 | -15.29M | -1.33M | -2.24M | -3.75M | -312.92K | 290.00 | 1.79K | 565.00 | 1.21K | 404.00 | -4.23K | 2.40K | 1.33K | 2.33K | 0.00 | 0.00 | 0.00 |
| Operating Expenses | 32.73M | 23.27M | -3.39K | -3.69M | -1.38M | -946.42K | -1.07M | 2.58M | 1.67M | 1.44M | 437.27K | 424.26K | 551.84K | 1.05M | 324.57K | 233.87K | 114.12K | 129.06K | 8.58K |
| Cost & Expenses | 32.81M | 23.27M | -3.39K | -3.69M | -1.38M | -946.42K | -1.07M | 2.58M | 1.67M | 1.44M | 437.27K | 424.26K | 551.84K | 1.05M | 324.57K | 233.87K | 114.12K | 129.06K | 8.58K |
| Interest Income | 0.00 | 891.21K | 136.73K | 3.15K | 39.48 | 9.13K | 12.27K | 5.16K | 3.63K | 7.09K | 12.00K | 16.90K | 38.01K | 13.36K | 2.90K | 2.73K | 0.00 | 0.00 | 0.00 |
| Interest Expense | 0.00 | 0.00 | 979.00 | 46.10K | 27.00K | 23.82K | 15.63K | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Depreciation & Amortization | 82.58K | 15.27K | 15.27K | 15.26K | 15.26K | 14.25K | 12.97K | 232.68 | 907.21 | 434.31 | 1.11K | 392.08 | 1.72K | 2.51K | 1.29K | 154.20 | 12.72K | 5.10K | -1.13K |
| EBITDA | -4.77M | -30.67M | -15.13M | -8.69M | -3.97M | -6.67M | -4.96M | -3.22M | -2.18M | -1.80M | -2.61K | -462.53K | -68.23K | -1.01M | 255.79K | -233.72K | -114.12K | -129.06K | -8.58K |
| EBITDA Ratio | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
| Operating Income | -32.81M | -23.27M | -15.29M | 3.69M | 1.38M | 946.42K | -3.82M | -2.58M | -1.67M | -1.44M | -437.27K | -424.26K | -1.20M | -1.05M | -324.57K | -233.87K | -114.12K | -129.06K | -8.58K |
| Operating Income Ratio | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
| Total Other Income/Expenses | 28.02M | 2.97M | 3.74M | -6.84M | -85.10K | 0.00 | -1.59M | 634.11K | 481.60K | -1.24M | -7.71M | 55.56K | 202.71K | -37.17K | -595.34K | 2.51K | 0.00 | 0.00 | 0.00 |
| Income Before Tax | -4.79M | -20.30M | -11.55M | 3.69M | 1.38M | 946.42K | 1.07M | -2.58M | -1.70M | -2.68M | -8.15M | -368.69K | -995.72K | -1.09M | -919.91K | -231.36K | 0.00 | 0.00 | 0.00 |
| Income Before Tax Ratio | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
| Income Tax Expense | 62.85K | -152.62K | 30.73K | 6.58M | -72.25K | 343.74K | 1.59M | 638.59K | 547.97K | 2.05M | 8.45M | -44.35K | -200.92K | -24.03K | 601.48K | 12.46K | -12.72K | -5.10K | 1.13K |
| Net Income | -4.79M | -20.30M | -11.58M | -2.89M | 1.38M | 602.68K | 1.07M | -2.58M | -1.70M | -2.68M | -8.15M | -368.69K | -995.72K | -1.08M | -900.74K | -228.81K | -98.93K | -116.41K | -8.58K |
| Net Income Ratio | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
| EPS | -0.29 | -1.30 | -0.75 | -0.64 | 1.94 | 1.04 | 2.49 | -7.61 | -5.88 | -10.76 | -138.07 | -6.25 | -16.93 | -33.02 | -49.58 | -25.62 | -20.45 | -27.92 | -4.18 |
| EPS Diluted | -0.29 | -1.30 | -0.75 | -0.64 | 1.94 | 1.04 | 2.49 | -7.32 | -5.88 | -10.76 | -138.07 | -6.25 | -16.93 | -33.02 | -49.58 | -25.62 | -20.45 | -27.92 | -4.18 |
| Weighted Avg Shares Out | 16.45M | 15.62M | 15.49M | 4.52M | 713.89K | 579.66K | 427.81K | 339.71K | 288.44K | 249.18K | 59.00K | 59.00K | 58.83K | 32.67K | 18.17K | 8.93K | 4.84K | 4.17K | 2.05K |
| Weighted Avg Shares Out (Dil) | 16.45M | 15.62M | 15.49M | 4.52M | 713.89K | 579.66K | 427.82K | 352.98K | 288.44K | 249.18K | 59.00K | 59.00K | 58.83K | 32.67K | 18.17K | 8.93K | 4.84K | 4.17K | 2.05K |
BriaCell Receives Green-Light from Data Safety Monitoring Board for its Phase 3 Study in Metastatic Breast Cancer
PHILADELPHIA and VANCOUVER, British Columbia, Dec. 02, 2024 (GLOBE NEWSWIRE) -- BriaCell Therapeutics Corp. (Nasdaq: BCTX, BCTXW) (TSX: BCT) (“BriaCell” or the “Company”), a clinical-stage biotechnology company that develops novel immunotherapies to transform cancer care, announces that the Data Safety...
BriaCell 2024 SABCS® Spotlight Poster to Showcase Positive Overall Survival Data Across All Patient Subtypes in Metastatic Breast Cancer
PHILADELPHIA and VANCOUVER, British Columbia, Nov. 26, 2024 (GLOBE NEWSWIRE) -- BriaCell Therapeutics Corp. (Nasdaq: BCTX, BCTXW) (TSX: BCT) (“BriaCell” or the “Company”), a clinical-stage biotechnology company that develops novel immunotherapies to transform cancer care, will be highlighting its positive...
BriaCell Provides Update to its Board of Directors
PHILADELPHIA, Pa. and VANCOUVER, British Columbia, Nov. 25, 2024 (GLOBE NEWSWIRE) -- BriaCell Therapeutics Corp. (Nasdaq: BCTX, BCTXW) (TSX: BCT) (“BriaCell” or the “Company”), a clinical-stage biotechnology company that develops novel immunotherapies to transform cancer care, announces that it has...
BriaCell Announces First Patient Dosed with Bria-OTS™ in Metastatic Breast Cancer Study
PHILADELPHIA and VANCOUVER, British Columbia, Nov. 21, 2024 (GLOBE NEWSWIRE) -- BriaCell Therapeutics Corp. (NASDAQ: BCTX, BCTXW) (TSX: BCT) a clinical-stage biotech company that develops novel immunotherapies to transform cancer care, announces that the first patient was dosed in its...
BriaCell Showcases Robust Anti-Cancer Activity of Personalized Off-the-Shelf Immunotherapy Pipeline at the 2024 SITC Conference
PHILADELPHIA and VANCOUVER, British Columbia, Nov. 08, 2024 (GLOBE NEWSWIRE) -- BriaCell Therapeutics Corp. (Nasdaq: BCTX, BCTXW) (TSX: BCT) (“BriaCell” or the “Company”), a clinical-stage biotechnology company that develops novel immunotherapies to transform cancer care, today is pleased to report...
BriaCell Overall Survival Data Selected for Spotlight Poster at 2024 San Antonio Breast Cancer Symposium®, December 10 – 13
PHILADELPHIA and VANCOUVER, British Columbia, Nov. 04, 2024 (GLOBE NEWSWIRE) -- BriaCell Therapeutics Corp. (Nasdaq: BCTX, BCTXW) (TSX: BCT) (“BriaCell” or the “Company”), a clinical-stage biotechnology company that develops novel immunotherapies to transform cancer care, announces five posters, including a...
BriaCell Therapeutics: High-Potential In Phase 3 Metastatic Breast Cancer, But Financing Concerns
BriaCell Therapeutics' lead candidate, Bria-IMT, shows promising trial results for metastatic breast cancer, potentially doubling overall survival and median progression-free survival. Despite a market cap below $30 million, BriaCell could tap into a $1-$5 billion market upon approval, with valuations...
BriaCell Reports Outperforming Metastatic Breast Cancer Patients and Standard-Beating Survival Data
PHILADELPHIA and VANCOUVER, British Columbia, Oct. 22, 2024 (GLOBE NEWSWIRE) -- BriaCell Therapeutics Corp. (Nasdaq: BCTX, BCTXW) (TSX: BCT) (“BriaCell” or the “Company”), a clinical-stage biotechnology company that develops novel immunotherapies to transform cancer care, announces new positive survival data,...
BriaCell Provides Phase 3 Clinical Engagement Update in Metastatic Breast Cancer Pivotal Study
PHILADELPHIA and VANCOUVER, British Columbia, Oct. 15, 2024 (GLOBE NEWSWIRE) -- BriaCell Therapeutics Corp. (NASDAQ: BCTX, BCTXW) (TSX: BCT) (“BriaCell” or the “Company”), a clinical-stage biotechnology company that develops novel immunotherapies to transform cancer care, today provides a clinical engagement...
BriaCell Therapeutics Announces Closing of $5 Million Offering
PHILADELPHIA and VANCOUVER, British Columbia, Oct. 02, 2024 (GLOBE NEWSWIRE) -- BriaCell Therapeutics Corp. (Nasdaq: BCTX, BCTXW) (TSX: BCT) (“BriaCell” or the “Company”), a clinical-stage biotechnology company that develops novel immunotherapies to transform cancer care, today announced the closing of...
Source: https://incomestatements.info
Category: Stock Reports